Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia

Neoplasia

Volumn 8, Issue 6, 2006, Pages 437-445

  Crowell, Pamela L ^a,b   Schmidt, C Max ^a,b,c,d,e   Yip Schneider, Michele T ^a,b   Savage, Jesse J ^b   Hertzler II, Dean A ^b   Cummings, William O ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e 357 Med Res and Libary Building   (United States)

Author keywords

Chemical carcinogenesis; COX 2; Pancreatic neoplasms; PanIN; Sulindac

Indexed keywords

BIS(2 OXOPROPYL)NITROSAMINE; CARCINOGEN; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; HAMSTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33745833966     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.04700     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 2, 106-130.
2. McKenna S and Eatock M (2003). The medical management of pancreatic cancer: a review. Oncologist 8, 149-160.
3. Ding XZ, Tong WG, and Adrian TE (2001). Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 1, 291-299.
4. Ricchi P, Zarrilli R, Di Palma A, and Acquaviva AM (2003). Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88, 803-807.
5. Subbaramaiah K and Dannenberg AJ (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24, 96-102.
6. Shaheen NJ, Straus WL, and Sandler RS (2002). Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 94, 950-963.
7. Chu J, Lloyd FL, Trifan OC, Knapp B, and Rizzo MT (2003). Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2, 1-7.
8. Ding XZ, Tong WG, and Adrian TE (2000). Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 20, 2625-2631.
9. Eibl G, Reber HA, Wente MN, and Hines OJ (2003). The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26, 33-41.
10. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, and Sinicrope FA (1999). Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal antiinflammatory drugs. Cancer Res 59, 4356-4362.
11. Perugini RA, McDade TP, Vittimberga FJ Jr, Duffy AJ, and Callery MP (2000). Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 4, 24-32 (discussion, 32-23).
12. Tseng WW, Deganutti A, Chen MN, Saxton RE, and Liu CD (2002). Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 6, 838-843 (discussion, 844).
13. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, and Marshall MS (2001). Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298, 976-985.
14. Agoff SN, Crispin DA, Bronner MP, Dail DH, Hawes SE, and Haggitt RC (2001). Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol 14, 139-146.
15. Aoki T, Nagakawa Y, Tsuchida A, Kasuya K, Kitamura K, Inoue K, Ozawa T, Koyanagi Y, and Itoi T (2002). Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol Rep 9, 761-765.
16. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, and Yoshida S (2001). Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91, 333-338.
17. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, and Rhee JC (2002). Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 17, 914-921.
18. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, and Imamura M (1999). Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 26, 69-76.
19. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron JL, Hruban RH, and Wilentz RE (2002). Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118, 194-201.
20. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, et al. (2001). Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 24, 447-452.
21. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F, and Saisho H (2002). Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary - mucinous tumors of the pancreas. Cancer 94, 1565-1573.
22. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, et al. (1999). Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5, 2018-2024.
23. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, and Beger HG (2002). Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25, 26-30.
24. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59, 987-990.
25. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, and Sweeney CJ (2000). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21, 139-146.
26. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, et al. (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25, 579-586.
27. Burke YD, Ayoubi AS, Werner SR, McFarland BC, Heilman DK, Ruggeri BA, and Crowell PL (2002). Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 22, 3127-3134.
28. Egami H, Takiyama Y, Cano M, Houser WH, and Pour PM (1989). Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group - related antigens. Carcinogenesis 10, 861-869.
29. Anderson KE, Johnson TW, Lazovich D, and Folsom AR (2002). Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94, 1168-1171.
30. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, and Thun MJ (2004). Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96, 524-528.
31. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, and Fuchs CS (2004). A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96, 22-28.
32. Menezes RJ, Huber KR, Mahoney MC, and Moysich KB (2002). Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2, 18.
33. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, and Shapiro S (2000). Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomark Prev 9, 119-123.
34. Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K, and Hirose M (2003). A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine - induced pancreatic carcinogenesis in hamsters. Int J Cancer 104, 269-273.
35. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, and Miller MS (2002). The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128, 525-532.
36. Standop J, Schneider MB, Ulrich A, and Pour PM (2001). Experimental animal models in pancreatic carcinogenesis: lessons for human pancreatic cancer. Dig Dis 19, 24-31.
37. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, and Hayashi Y (1990). Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2- oxopropyl)amine. Carcinogenesis 11, 393-395.
38. Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA, and Muller JM (2002). Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2, 54-60.
39. Hwang DH, Fung V, and Dannenberg AJ (2002). National Cancer Institute workshop on chemopreventive properties of nonsteroidal antiinflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 4 (2), 91-97.